Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 5/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3991039 | 0.77 | LMNA (0.34) | TRPA1CYP3A4SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL15467266 | 0.75 | SMYD2 (0.34) | TRPA1CYP3A4SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL13915435 | 0.75 | TRPA1 (0.37) | TRPA1CYP3A4SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4914439 | 0.75 | TAAR1 (0.41) | CYP3A4SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL16634021 | 0.75 | TAAR1 (0.41) | CYP3A4SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4766097 | 0.75 | TRPA1 (0.37) | TRPA1CYP3A4SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL15467267 | 0.75 | SMYD2 (0.34) | TRPA1CYP3A4SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL21379413 | 0.75 | CYP3A4 (0.33) | CYP3A4SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL21379414 | 0.75 | CYP3A4 (0.33) | CYP3A4SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4735366 | 0.75 | TRPA1 (0.37) | TRPA1CYP3A4SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2019094-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | CLIC4, NR3C2, MAN2B1 | TRPA1 441/4885CNR1 9/4885CYP3A4 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.